Dr. Wood has 25 years’ experience championing innovative clinical solutions into routine clinical use. She was recognized as one of the top 50 CEOs by Healthcare Technology Report; she also received the Joe Rosenfeld Award for outstanding leadership. In addition to serving as CEO of VIDA, she is currently a board member for iCAD, serves on the Board of Governors at the University of Maryland, and is past Chair of the Board of Visitors of the Graduate School at Duke University. Dr. Wood received her Ph.D. from Johns Hopkins Medical Institutions, School of Hygiene and Public Health. Her Ph.D. work combined quantifying three-dimensional lung structure with changes in lung function using high-resolution CT imaging. She also holds a Master of Science degree in Biomedical Engineering from Duke University, and a Bachelor of Science in Engineering from the University of Maryland, College Park.
AI & Data Science Showcase:
VIDA delivers precision lung intelligence to accelerate the therapy pipeline. Our AI-powered analysis is quantitative and actionable, making a breakthrough in the staggering time and cost of respiratory trials.
The Disruptive Impact of Precision Lung Data on Respiratory Trial
Lung clinical trials are expensive & time consuming. Learn how data is harnessed to accelerate respiratory trials by delivering superior endpoints, identifying subjects and streamlining operations. Through AI and precision lung metrics, we're making breakthroughs in the staggering time and cost of trials.
The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.